<DOC>
	<DOCNO>NCT00006260</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Drugs mesna may effective prevent side effect chemotherapy . PURPOSE : Phase II trial study effectiveness combination chemotherapy consist etoposide ifosfamide give mesna , cisplatin treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate patient metastatic breast cancer treat etoposide , ifosfamide mesna , cisplatin . - Determine tolerability toxicity regimen patient . OUTLINE : Patients stratify accord number prior chemotherapy course metastatic disease ( 0 vs 1 ) . Patients receive etoposide IV 60-90 minute , cisplatin IV 30 minute , ifosfamide IV 30 minute day 1-3 . Mesna administer IV 15 minute 30 minute prior 4 hour ifosfamide , orally 8 hour post infusion . Treatment continue every 28 day absence unacceptable toxicity disease progression . Patients follow every 3 month . PROJECTED ACCRUAL : At least 36 patient ( 16 per stratum ) accrue 36 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven progressive metastatic breast cancer Measurable disease Any lesion measurable 2 dimension Hepatic metastasis sum measurement costal margin midclavicular line tip xiphoid process great 5 cm quiet respiration Hepatic defect clearly measurable radionuclide , CAT , MRI scan Bone metastasis consider measurable disease Evaluable disease allow measurable disease also present No brain metastasis , carcinomatous meningitis , spinal cord compression Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Not specify Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Hemoglobin least 10 g/dL WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 1.5 mg/dL No bladder outlet obstruction Cardiovascular : No symptomatic cardiovascular disease ( e.g. , congestive heart disease ) inability tolerate fluid load Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection No prior malignancy except adequately treat basal squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No great 1 prior biologic response modifier treatment metastatic disease Chemotherapy : No great 1 prior chemotherapy regimen metastatic disease allow Patients relapse within 6 month adjuvant chemotherapy consider fail 1 regimen Patients relapse 6 month adjuvant chemotherapy consider prior regimen Greater 4 week since prior chemotherapy ( great 6 week mitomycin nitrosoureas ) recover No prior cisplatin , etoposide , ifosfamide Endocrine therapy : Prior medical surgical hormonal therapy allow Radiotherapy : Prior radiation therapy area measurable disease allow indicator lesion increase size great 25 % treatment Recovered effect prior radiotherapy Surgery : Recovered effect major surgery Other : At least 7 day since prior nephrotoxic drug ( e.g. , aminoglycosides , diuretic , lithium , intravenous contrast , nonsteroidal antiinflammatory drug )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>